Abstract: In a fermentation procedure for the production of nucleosides i.e. inosine and/or guanosine using an adenine-requiring microorganism, the fermentation is carried out by allowing a source of adenine to be present in the medium in an excess amount over the amount of adenine that would be conductive to a maximum yield of inosine and/or guanosine in aerobic culture using ordinary air, and cultivating the microorganism while an oxygen-rich gas is bubbled into the medium. Thus, inosine and/or guanosine are accumulated in high yield in the fermentation broth.
Type:
Grant
Filed:
November 24, 1982
Date of Patent:
March 25, 1986
Assignee:
Takeda Chemical Industries, Ltd.
Inventors:
Yasuhiro Sumino, Koji Sonoi, Muneharu Doi
Abstract: Monoclonal antibodies 703D4 and 704A1 detect human non-small cell lung cancer (non-SCLC) and distinguish non-SCLC from all other types of lung cancer and normal tissue cells. These two antibodies may be utilized in kit form to distinguish non-SCLC from other forms of lung cancer. These monoclonal antibodies bind to S.sup.35 methionine-incorporating protein doublets under reduced and unreduced conditions. The determinants bound by these antibodies on the 31 kiladalton protein are independent of each other as determined in radiolabelled competition assays.
Type:
Grant
Filed:
May 18, 1983
Date of Patent:
February 11, 1986
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Hybrid-myeloma cells which produce monoclonal antibody specific to the .beta. subunit of human chorionic gonadotropin and methods of use of the monoclonal antibody.
Type:
Grant
Filed:
November 16, 1981
Date of Patent:
January 21, 1986
Assignee:
The Reagents of the University of Michigan
Inventors:
Mohammad B. Khazaeli, William H. Beierwaltes, Barry G. England
Abstract: This invention relates to a kit for the detection of microbial nucleic acids and a method for identifying the nucleic acids using a one-step sandwich hybridization technique. The technique requires two complementary nucleic acid reagents for each microbe or group of microbes to be identified.
Abstract: The present invention concerns novel immunoprecipitating autologous antibodies which recognize the Class 1 gp90 antigen on melanoma cells. These antibodies, optionally tagged with a chromophoric or radioactive label and immobilized on an inert support, may be used to recognize and isolate the gp90 antigen from melanoma cell extracts. Monoclonal antibodies to melanoma may be screened with the gp90 antigen for those which recognize epitopes other than the FD antigenic system.The cell line containing the gp90 antigen which has been cultured in vitro is a source of gp90 antigen for generation of monoclonal antibodies which will be useful in analyzing the gp90 antigen for those epitopes which may be of diagnostic value in immunoassay of melanoma.
Type:
Grant
Filed:
April 1, 1983
Date of Patent:
December 31, 1985
Assignee:
Sloan-Kettering Institute
Inventors:
Francisco X. Real, M. Jules Mattes, Alan N. Houghton, Philip O. Livingston, Kenneth O. Lloyd, Herbert F. Oettgen, Lloyd J. Old
Abstract: A method and test kit are disclosed for detecting the presence of hepatitis B virus in a test specimen containing at least a portion of the DNA of the virus. A test reagent comprises cloned hepatitis B virus-DNA that has been repurified by treatment with a restriction enzyme and labelled to high specific activity with a radioactive label. The sample to be tested is fixed to a solid matrix, incubated in the presence of the test reagent under hybridization conditions and detected by hybridization to the labelled DNA probe. The uncombined HBV-DNA (labelled) is removed from the substrate, and the hybridized HBV-DNA determined by scintillation counting or by autoradiography of the substrate.
Type:
Grant
Filed:
March 31, 1981
Date of Patent:
December 31, 1985
Assignee:
Albert Einstein College of Medicine, A Division of Yeshiva Univ.
Abstract: In a particle agglutination assay for an antigen (Ag), there is included in the mixture a limited amount of a substance which binds univalently with a proportion of the Ag present, that Ag which is so bound being unable then to cause agglutination of the particles. In this way, unusually large concentrations of Ag can be assayed in that a proportion of the Ag is bound to the univalent substance and the particle agglutination assay is in effect conducted on the smaller amount of Ag still remaining free in solution.
Type:
Grant
Filed:
August 4, 1983
Date of Patent:
December 3, 1985
Assignee:
International Institute of Cellular & Molecular Pathology
Inventors:
Daniel Collet-Cassart, Jean-Claude Mareschal, Pierre L. Masson
Abstract: Early pregnancy can be determined by detection of a protein in serum, which protein is associated with the placental membrane. The protein is characterized by having an approximate molecular weight of 47,000 to 53,000 and an isoelectric point of from about 4.0-4.4.
Abstract: A monoclonal antibody which specifically binds to the surface recognition structure of a predetermined mature human T cell clone, which recognition structure renders the clone capable of acting as causative agent in a predetermined autoimmune disease, the monoclonal antibody being capable of specifically binding to the recognition structure of the clone to inhibit the ability of the clone to act as a causative agent in the predetermined autoimmune disease.
Type:
Grant
Filed:
February 16, 1983
Date of Patent:
October 29, 1985
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Ellis L. Reinherz, Stuart F. Schlossman, Stefan C. Meuer
Abstract: A method of diagnosis using an attached material for binding to an immune complex, by treating the bound complex with a series of different reagents or mixtures thereof and detecting the presence or absence of reaction in each case, this method being based on immune complexes produced in the body during infection and allowing much earlier detection and diagnosis of infection thereby providing the facility for treatment to reduce the damage caused to the body by the formation of complex.
Abstract: A hybridoma cell line is disclosed that secretes monoclonal antibodies which serve as a high titer, reproducible, biological reagent useful in biological/medical research for isolating and identifying phosphotyrosine-containing proteins. In addition, the antibodies have potential uses in diagnosis of a variety of diseases, including certain cancers. The antibodies, which have demonstrated affinity for a variety of molecules containing o-phosphotyrosine residues, were prepared using a synthetic analog, p-azobenzyl phosphonate (ABP) covalently linked to a carrier protein, as the antigen.
Type:
Grant
Filed:
December 13, 1982
Date of Patent:
September 24, 1985
Assignee:
Massachusetts Institute of Technology
Inventors:
A. Raymond Frackelton, Jr., Herman N. Eisen, Alonzo H. Ross
Abstract: There is provided an assay for the determination of the carcinogenicity of chemical and physical agents, by exposing a selected line of tumor virus transformed cells to the agent to be tested and determining whether such exposure induces endogenous viral DNA replication in such cells, which induction is indicative of the carcinogenicity of the tested agent by in situ hybridization. There is provided a kit for carrying out such assay.
Type:
Grant
Filed:
March 23, 1982
Date of Patent:
July 30, 1985
Assignee:
Yeda Research and Development Company Ltd.
Abstract: Antibodies and antigens are disclosed which provide a method of detecting and a method of combating flukes. A diagnostic method for the determination of an active fluke infection in a warm-blooded animal is provided which comprises the testing of body serum or body fluids for the presence of fluke spine glycoprotein or anti-spine antibodies. Fused cell hybrids ATCC HB-8086, ATCC HB-8087 and ATCC HB-8088, as well as the antibodies produced by the fused cell hybrids, are also provided.
Abstract: Method of separating A.sub.14 -.sup.125 I-insulin from heterogeneously labeled insulin molecules for biological studies which involves iodating insulin in a controlled manner, selectively absorbing the insulin from the iodination procedure in a tightly packed bed of octadecylsilane bonded to silica employing reverse phase liquid chromatography principles, thereafter eluting large and small radioactive and nonradioactive materials such as damaged insulin, various contaminants and polar materials from the bed with dilute trifluoroacetic acid, thereafter eluting the intact .sup.125 I-insulin from the bed with a mixture of acetonitrile and dilute trifluoroacetic acid and then separating the A.sub.14 -insulin by high performance liquid chromatography or ion exchange chromatography.
Type:
Grant
Filed:
December 27, 1982
Date of Patent:
July 9, 1985
Assignee:
University of TN Research Corporation
Inventors:
Frankie B. Stentz, Reba K. Wright, Abbas E. Kitabchi
Abstract: The present invention relates to the preparation of mixtures of sterically hindered substituted N-secondary amino acids or their alkali metal salts by a one-step reductive condensation of an amino acid or its alkali metal salt containing a primary amino group and a ketone to thereby form a mono-substituted amino acid or alkali metal salt thereof, followed by preparing the corresponding sterically hindered tertiary amino acids or alkali metal salt thereof by reacting the mono-substituted amino acids or alkali metal salt thereof with an unhindered aldehyde under reducing conditions in the presence of a hydrogenating catalyst. The novel mixtures of the sterically hindered mono-substituted amino acids and the tertiary amino acids and their alkali metal salts are useful promoters for alkaline salts in "hot pot" acid gas scrubbing processes.
Abstract: Preparations useful in the diagnosis of infectious mononucleosis are disclosed. Horse and sheep erythrocytes are purified and essentially homogenous glycoproteins are extracted. The purified glycoproteins are useful as antigens in testing for the presence of the heterophile antibodies of infectious mononucleosis and in the preparation of reagents for the enumeration of rosetting lymphocytes without having to have available fresh sheep blood.
Abstract: This invention relates to the detection of antibodies in sera of AIDS and pre-AIDS patients and describes the biochemical and immunological analysis of antigens associated with the virus HTLV-III Human T-Cell Leukemia Virus. It is shown that antigens associated with the infection of human cells by this virus are specifically recognized by antibodies from AIDS patients. Specifically, HTLV-III isolated from AIDS patients and transmitted by cocultivation with an HT cell line is specifically detected by antibodies from human sera taken from AIDS patients. The method of detection of antibodies preferred is a strip radioimmunoassay (RIA) based on the Western Blot technique or an ELISA (an enzyme-linked immunosorbent assay) or an indirect immunofluorescence assay.
Type:
Grant
Filed:
April 23, 1984
Date of Patent:
May 28, 1985
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
Abstract: A reagent and the protocol for the treatment of Graft Versus Host Disease is disclosed. Monoclonal antibodies specific for T-lymphocytes in human donor bone marrow are covalently linked to separate ricin toxin, combined in a mixture to form a treatment reagent, and combined with bone marrow removed from a human donor. The bone marrow-reagent mixture is then infused into an irradiated recipient. This protocol virtually eliminates T-lymphocyte activity, the cause of Graft Versus Host Disease.
Type:
Grant
Filed:
January 7, 1983
Date of Patent:
May 28, 1985
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
David M. Neville, Jr., Richard J. Youle